financetom
Business
financetom
/
Business
/
Alaska Airlines, Hawaiian Airlines extend review period of deal amid antitrust scrutiny
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Alaska Airlines, Hawaiian Airlines extend review period of deal amid antitrust scrutiny
Jul 30, 2024 4:10 AM

(Reuters) - Alaska Air Group ( ALK ) has agreed to extend the review period for the proposed $1.9 billion acquisition of rival Hawaiian Airlines amid antitrust scrutiny from the U.S. Department of Justice, the carrier said in a filing on Tuesday.

"Our airlines have mutually agreed with the DOJ on a brief extension of the formal review period until August 15," Alaska Air Group ( ALK ) said.

The deal, announced last year, has been under antitrust review and both carriers said in March they "have been working cooperatively with the DOJ and expect to continue to do so".

Shortages of new planes, jet engines and pilots have spurred U.S. airlines to pursue growth through acquisitions, putting them in the crosshairs of anti-trust regulators who have generally been wary of mergers between smaller airlines.

The takeover would give Alaska Air ( ALK ) control of more than 50% of the market for flights to Hawaii, one of the world's top holiday designations.

The airlines, in March, entered a timing agreement with the DOJ, under which the carriers agreed not to consummate the deal within 90 days after submitting antitrust-related information.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Why Is Immuno-Oncology Focused Aptevo Therapeutics Stock Trading Higher On Thursday?
Why Is Immuno-Oncology Focused Aptevo Therapeutics Stock Trading Higher On Thursday?
Mar 7, 2024
Thursday, Alligator Bioscience AB and Aptevo Therapeutics Inc ( APVO ) released interim data from the dose escalation phase of their Phase 1 trial evaluating ALG.APV-527 for solid tumors likely to express the tumor antigen 5T4. The multi-center, dose-escalation trial is now more than 50% enrolled, and preliminary results include: Treatment was overall well-tolerated, and a maximum tolerated dose has not yet been determined. Dose...
EV maker Rivian unveils smaller, less expensive SUVs, crossovers
EV maker Rivian unveils smaller, less expensive SUVs, crossovers
Mar 7, 2024
LAGUNA BEACH, California (Reuters) -Rivian on Thursday unveiled its smaller and less expensive R2 SUVs and R3 crossovers amid a slowdown in demand for EVs and also said it would start producing the R2 at its existing facility in Illinois to ensure deliveries in 2026. Rivian shares were up 10% at $12.16 on Thursday afternoon. The R2, with a starting...
Albemarle Unusual Options Activity
Albemarle Unusual Options Activity
Mar 7, 2024
Investors with a lot of money to spend have taken a bullish stance on Albemarle . And retail traders should know. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with ALB,...
CompoSecure Shares Rise After Q4 Results Top Estimates
CompoSecure Shares Rise After Q4 Results Top Estimates
Mar 7, 2024
01:44 PM EST, 03/07/2024 (MT Newswires) -- CompoSecure ( CMPO ) shares jumped 30% in recent Thursday trading, a day after the company reported Q4 earnings and revenue that topped estimates by analysts. The company on Wednesday reported Q4 adjusted diluted earnings of $0.26 a share, up from $0.20 a year earlier. Analysts polled by Capital IQ expected $0.23. Revenue...
Copyright 2023-2025 - www.financetom.com All Rights Reserved